anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Subxiphoid video-assisted thoracoscopic surgery (VATS) is considered a safe and feasible operation for anterior mediastinal mass resection. However, diaphragmatic injury, presented as tearing or puncturing, may occur during subxiphoid VATS despite of low incidence. This study aims to explore risk factors for diaphragmatic injury in subxiphoid VATS, as well as strategies to reduce occurrence of the injury.
METHODS: We retrospectively reviewed clinical records of 44 consecutive adult patients who underwent subxiphoid VATS. These patients were divided into two groups: diaphragmatic injury group and non-injury group. Perioperative outcomes and anatomic features derived from 3D CT reconstructions were compared between the two groups.
RESULTS: Significant differences were observed in operation time (223.25 ± 92.57 vs. 136.28 ± 53.05, P = 0.006), xiphoid length (6.47 ± 0.85 vs. 4.79 ± 1.04, P = 0.001) and length of the xiphoid below the attachment point on the diaphragm (24.86 ± 12.02 vs. 14.61 ± 9.25, P = 0.029). Odds ratio for the length of the xiphoid below the attachment point on the diaphragm was 1.09 (1.001-1.186), P = 0.048 by binary logistic regression analysis.
CONCLUSIONS: We identified the length of the xiphoid below the attachment point on the diaphragm as an independent risk factor for diaphragm injury during subxiphoid VATS. Prior to subxiphoid VATS, a 3D chest CT reconstruction is recommended to assess the patients' anatomic variations within the xiphoid process. For patients with longer xiphoid process, a higher incision at the middle and upper part of the xiphoid process, and partial xiphoid process resection or xiphoidectomy is preferred.
Each program participant will receive a fruit and vegetable prescription that is written by pediatricians to exchange for $15 of fresh produce. Prescriptions will be distributed during pediatric office visits and are redeemable at a local farmers' market and mobile market.
As with all oligonucleotides, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In Study 1, 3 (2.5%) patients treated with AMVUTTRA developed anti-drug antibodies. Although anti-drug antibody development was not found to affect the pharmacokinetics, safety, or efficacy of AMVUTTRA in these patients, the available data are too limited to make definitive conclusions.
Significant lethality after single oral doses was seen in female rats and mice at 552 mg/kg (3256 mg/m2) and 966 mg/kg (2898 mg/m2), respectively. In males, these values were slightly higher, 626 and 1280 mg/kg, respectively. There was no lethality in dogs at oral doses up to 200 mg/kg (4000 mg/m2).

No specific information is available on the treatment of overdosage with alendronate sodium. Hypocalcemia, hypophosphatemia, and upper gastrointestinal adverse events, such as upset stomach, heartburn, esophagitis, gastritis, or ulcer, may result from oral overdosage. Milk or antacids should be given to bind alendronate. Due to the risk of esophageal irritation, vomiting should not be induced and the patient should remain fully upright.

Dialysis would not be beneficial.
FIELD: antibiotics, pharmacy. SUBSTANCE: invention relates to new derivatives of erythromycin of the general formula (I)   where values Z, R 1 , R 2  are given in p. 1 of the invention claim. New derivatives of erythromycin show a bactericidal effect, in part, they show activity with respect to gram-positive and gram-negative bacteria. Invention describes also methods of their synthesis and a pharmaceutical composition based on compounds of the formula (I). EFFECT: improved method of synthesis of new erythromycin derivatives, valuable antibacterial properties. 12 cl, 20 ex
Triple-negative breast cancer (TNBC), the most aggressive subtype, presents a critical challenge due to the absence of approved targeted therapies. Hence, there is an urgent need to identify effective therapeutic targets for this condition. While epidermal growth factor receptor (EGFR) is prominently expressed in TNBC and recognized as a therapeutic target, anti-EGFR therapies have yet to gain approval for breast cancer treatment due to their associated side effects and limited efficacy. Here, we discovered that intercellular adhesion molecule-1 (ICAM-1) exhibits elevated expression levels in metastatic breast cancer and serves as a pivotal binding adaptor for EGFR activation, playing a crucial role in malignant progression. The activation of EGFR by tumor-expressed ICAM-1 initiates biased signaling within the JAK1/STAT3 pathway, consequently driving epithelial-to-mesenchymal transition and facilitating heightened metastasis without influencing tumor growth. Remarkably, ICAM-1-neutralizing antibody treatment significantly suppressed cancer metastasis in a breast cancer orthotopic xenograft mouse model. In conclusion, our identification of ICAM-1 as a novel tumor intrinsic regulator of EGFR activation offers valuable insights for the development of TNBC-specific anti-EGFR therapies.
Solved diagnosis case data is stored by utilizing a redundant discrimination net as a dynamic memory. The stored diagnosis case data is incorporated to form scientific descriptions within a medical knowledge base and heuristics within an empirical knowledge base. Diagnosis hypotheses are generated using an initial symptom description, the dynamic memory, and the medical knowledge base. The initial symptom description is received from an end user. A subset of the diagnosis hypotheses is created to form one or more solution cases. The one or more solution cases are presented to a subject matter expert. A diagnosis success or a diagnosis failure identifying, based on a response received from the subject matter expert, to form an assessed solution case. An assessed solution case is converted into experiences. The experiences are inputted into the dynamic memory. Data containing the assessed solution case is transmitted to a medical artificial intelligence analytics application.
The present invention provides compound red sage root and amino acid infusion which comprises red sage root with bioactivity, rosewood and amino acid for providing nutrition and energy. The present invention is characterized in that each bottle of infusion comprises 6 to 20g of crude medicine of extracts of the red sage root and the rosewood; the rest are the amino acid and medical assistant materials. Effective components in an extract of compound red sage root in ordinary solution have high instability; however, under the existence of the amino acid of the comprehensive functions of complexation, antioxidation, shielding, etc. in all kinds of solution, main active components of flavone and coffee acyl are stable (like in an original plant body). Therefore, when the compound red sage root and amino acid infusion is placed for one year at ordinary temperature, the product is stable and reliable and does not have stimulation performance. Compared with the existing compound red sage root infusion, the present invention has strong functions at the aspects of activating blood circulation, dissipating blood stasis, reducing qi, relieving pain, supplementing the qi and raising yang.
OBJECTIVE: This study aimed to investigate the relationship between serum lactate levels at admission to the intensive care unit (ICU) and the clinical outcomes of children with sepsis.
METHODS: We used the Pediatric Intensive Care (PIC) database to identify 288 pediatric patients with sepsis. We analyzed the relationship between lactate levels and hospital and ICU mortality in sepsis by establishing a segmented multivariable Cox regression model. We also conducted subgroup analysis as well as analyzed the restricted cubic spline curves.
RESULTS: After adjusting for all potential confounding factors, an increase of 1 mmol/L in lactate levels was found to be associated with an 17% rise in the 28-day hospital mortality risk among sepsis patients (HR: 1.17, 95% CI: 1.08-1.27, P = 0.0002). When considering lactate as a categorical variable, the mortality risk of patients with lactate levels ≥ 2.2 mmol/L was significantly increased (HR: 3.61, 95% CI: 1.24-10.54, P = 0.0189). The restricted cubic spline curve analysis revealed a nonlinear correlation between lactate and 28-day mortality, with an inflection point at 2.2 mmol/L. Similar findings were also observed in the assessment of secondary outcomes.
CONCLUSIONS: Our study demonstrates a non-linear correlation between lactate levels and 28-day mortality in pediatric sepsis, with a critical threshold of 2.2mmol/l for lactate levels in septic patients. Early assessment of lactate levels is recommended for children with sepsis to facilitate prompt intervention and mitigate the risk of fatality.
Respiratory viral infections are one of the most common causes of illness in the world. These infections are major causes of SARI and can lead to severe outcomes, including hospitalization and death. NTZ is a medication that is approved in the United States and Mexico to treat gastrointestinal parasitic diseases. This study will evaluate the use of NTZ to treat SARI. The purpose of this study is to evaluate the safety, effectiveness, and tolerability of NTZ, in combination with standard care, in treating SARI in people who are hospitalized.

Participants will be hospitalized and study entry assessments will include medical assessments, blood collection, and a nasopharyngeal swab or wash. Participants will then be randomly assigned to receive NTZ or placebo for 5 days. Participants younger than 12 years will receive an oral suspension formulation of NTZ or placebo; participants 12 years and older will receive NTZ or placebo tablets. All participants will also receive standard of care treatment for acute severe viral respiratory infections, which may include antibiotics and/or treatment for influenza. They will be discharged from the hospital based on their doctors' recommendations. Participants will record their temperature and symptoms in a daily diary, which will be reviewed by study staff during study visits. Follow-up visits will occur on Days 3, 7, 14, and 28, and may occur as inpatient or outpatient visits. These visits may include the same assessments that occurred at baseline, as well as physical examinations, depending on the visit. Participants who are still hospitalized at Day 28 will be followed by study staff until they are discharged from the hospital.
Presented herein is a description for the manufacturing of inactivated HIV for use in vaccines against AIDS, as well as other inactivated viruses for other infectious diseases. This invention incorporates methods for inactivating infectious virus particles while retaining protein integrity and antigenicity. The methods utilize critical, near-critical or supercritical fluids with or without polar cosolvents. This invention would allow for the creation of HIV vaccines from genetically attenuated HIV strains for a greater degree of product safety, and from combinations of different HIV strains for broader protection. This HIV vaccine manufacturing technology is inexpensive, amenable to large-scale processing and portable, i.e. it can be readily implemented in a host country site. This invention can be utilized for other viral and bacterial infectious diseases, such as influenza and hepatitis.
Under ultrasound-guidance, the sciatic nerve can readily be identified in the posterior thigh. The nerve appears hyperechoic and can be traced distally to the popliteal fossa, where it divides into the tibial and common peroneal nerves. Local anesthesia is injected under real-time visualization following a negative aspiration. If a single-injection block is done, local anesthesia is deposited adjacent to the sciatic nerve within the fascial plane, but not within the epineurium. As such, single-injection sciatic PNB, which can last up to 24 hours, should provide adequate analgesia precluding the need for oral narcotic or nonsteroidal anti-inflammatory medications following ACL reconstruction with a hamstring autograft.
The present invention relates to ginkgo leaf extract and an extraction method thereof, which belongs to the technical field of traditional Chinese medicine preparation. The total content of total flavonoid and total terpene lactone in ginkgo leaf extract reaches more than 80%, wherein the content of the total flavonoid reaches more than 70%, the content of the flavonoid glycoside reaches more than 40%, and the content of the total terpene lactone reaches more than 10%. The extraction method comprises the procedures of extraction, purification, separation, concentration, drying, etc. Compared with the prior art, the present invention has more reasonable technical route, and the processes of extraction, trash elimination, purification, abstraction, column separation, refinement, etc. meet the requirements of mass production; the use of flocculant chitosan, a polyamide column, AB-8 macroporous resin, etc. is scientific and feasible; the present invention also has the advantages of low production cost, high extraction rate of effective constituents, industrialization condition possession, etc. The present invention simultaneously discloses infusion solution and powder injection which are prepared by the ginkgo leaf extract and preparation methods thereof. The infusion solution and the powder injection of ginkgo leaf extract have broad application to the field of the treatment of cardiovascular diseases.
The Phase I Thorough QT/QTc (TQT) study will be performed in a single center, the Vince \& Associates Clinical Research, Inc., clinical trials unit (CTU), according to a randomized, double-blinded (except for the use of moxifloxacin), placebo-controlled, four-period, four-treatment, crossover design balanced with respect to first-order carryover effect in 72 healthy male or female subjects, aged 18 to 45 years inclusive, to evaluate the effect of zoliflodacin on the corrected QT interval of the electrocardiogram (ECG) using Fridericia's Formula (QTcF) and other ECG parameters; the correlation of the drug concentrations (and pharmacokinetic (PK) profile) with time-matched, placebo-corrected, baseline-adjusted difference in QTcF interval (delta delta QTcF); and the PK and safety profiles of the new zoliflodacin formulation. Each subject will receive one dose of each of four treatments: zoliflodacin 2 g orally, zoliflodacin 4 g orally, placebo for zoliflodacin 4 g orally, and moxifloxacin 400 mg orally. The study will last approximately 12 weeks with a subject participation duration of up to 55 days. The primary hypothesis to be tested is that following administration of zoliflodacin 2 g and 4 g, the upper bound of the one-sided 95% confidence interval (CI) of treatment effect on delta delta QTcF is \> / = 10 msec for at least one of the ECG assessments, against the alternative hypothesis that all mean effects are \< 10 msec. The primary objective is to evaluate the effect of zoliflodacin on the corrected QT interval of the ECG using Fridericia's formula (QTcF). The secondary objectives are: 1) to evaluate the effects of zoliflodacin on other ECG parameters (PR, QRS, and RR intervals, and heart rate (HR)); 2) to evaluate the sensitivity of QTcF measurement using moxifloxacin; 3) to evaluate the effect of zoliflodacin on T-wave morphology; 4) to evaluate the PK of 2 g and 4 g oral zoliflodacin under fasting state; 5) to evaluate the relationship between zoliflodacin PK and time-matched QTcF pharmacodynamics (PD); 6) to evaluate the safety and tolerability of 2 g and 4 g oral zoliflodacin.
FIELD: medicine. SUBSTANCE: desired products have formula I where B, Cy, A, R 3  and R 4  have appropriate values. 4-alkoxyphenyl derivative having formula II where B, Cy, A and X are as mentioned above is used as reagent 1. Amine of HNR 3 R 4,  formula where R 3 , R 4  have appropriate values is used as reagent 2. Desired product is isolated in free state or as salt, if desired said salt may be converted into base, and if it is desired base is converted into salt. Structural formula of I and II are as follows:  . EFFECT: improves efficiency of the method.
Provided is a medicine management system capable of confirming a receipt status and a medication status of a delivered medicine even at a delivery source. The present invention comprises: a management server which manages the receipt status and the medication status of delivered medicine; a first terminal having a function of notifying the management server of information indicating receipt when the medicine is received; a second terminal having a function of notifying the management server of information indicating medication when medication is taken; and a third terminal having a function of acquiring information on the receipt status and the medication status of the medicine from the management server, and displaying the acquired information. The medicine includes a packaged medicine packaged on the basis of prescription information, and unique delivery identification information is given for each delivery. The delivery identification information is displayed on a delivered item that is to be delivered together with the medicine. Unique medicine identification information on the packaged medicine is given for each package and displayed on each of the sachets. The management server manages the medicine identification information in association with the delivery identification information and the information extracted from the prescription information. The first terminal reads the delivery identification information displayed on the delivery and notifies the management server of information indicating receipt. The second terminal reads the medicine identification information displayed on the sachet and notifies the management server of information indicating medication. The management server receives the notification of the information indicating the receipt from the first terminal to manage the receipt status of the medicine, and receives the notification of the information indicating the medication from the second terminal to manage the medication status of the medicine.
Remove one blister-packaged prefilled syringe from the refrigerated carton. Let the prefilled syringe stand at room temperature for 20 minutes to allow the solution to warm to room temperature. Visually inspect the syringe for particulate matter and discoloration prior to administration. The solution in the syringe should appear clear, colorless to slightly yellow. If particulate matter or discoloration is observed, discard the syringe.

Areas for subcutaneous self-injection include arms, abdomen, hips, and thighs. The prefilled syringe is for single use only. Discard unused portions.

Using an autoinjector that is not compatible for use with TEVA’s COPAXONE may increase the risk for medication errors, such as dose omission or administration of a partial dose [see Warnings and Precautions (5.6)].
Participants will receive a single dose of ustekinumab intravenously (IV) (weight-based dose approximating 6 milligrams per kilogram \[mg/kg\]) at Week 0. Participants with body weight less than or equal to (\<=) 55 kg will receive ustekinumab IV of 260 mg, greater than (\>) 55 kg and \<=85 kg will receive ustekinumab IV of 390 mg, and \>85 kg will receive ustekinumab IV of 520 mg at Week 0 in induction phase followed by ustekinumab 90 mg subcutaneously (SC) in maintenance phase from Week 8 to Week 52. For participants who achieve clinical response with ustekinumab induction dosing at Week 8, will continue to receive 90 mg ustekinumab SC every 12 weeks with final dose at Week 44. If these participants meet the criteria for loss of response from Week 16 to Week 40, dose can be adjusted to 90 mg every 8 weeks (q8w). Participants who are non-responders to ustekinumab at Week 8, and achieve clinical response at Week 16, will continue to receive ustekinumab 90 mg SC q8w from Week 16 to Week 48.
The invention is a notoginseng saponin slow release preparation, which includes effective ingredient notoginseng saponin and release regulator, diluter, lubricant and glidant. Its character lies in: the slow release preparation contains cellulose polymer framework material. In order to control and regulate the medicine release better, the surface active agent and diluter can be added into the preparation. The preparation can release notoginseng saponin 50% in 4-6 hours, and the releasing rate is not affected by media pH value. After the medicine is taken, the effective ingredients will be released with slow release medicine formulation character, in order to achieve the aim of release regulation. Its meaning lies in: it reduces the peak density of the medicine, prolongs the half life of medicine, and upgrades the compliance of medicine.
PURPOSE OF REVIEW: Summarize the evolution of the trauma-informed care (TIC) approach in pediatrics, highlight the importance of using this lens in pediatric obesity management and treating the whole patient and family, and suggest recommendations for providers to incorporate TIC into their practice.
RECENT FINDINGS: Implementing TIC in pediatric obesity management is recommended and offers an approach to address trauma-related symptoms associated with obesity. The TIC framework creates a safe, nurturing space to have open conversations with patients and families to promote resilience and reduce stigma related to obesity without re-traumatization. Screening tools may expose symptoms related to trauma, but are limited. Provider training is available and development of TIC related skills may be improved through using the arts and humanities. Success of TIC requires a tailored, integrated healthcare system approach with commitment from all levels.
SUMMARY: The TIC approach offers providers skills to uncover trauma-related symptoms and address obesity-related health disparities while reducing stigma. Collaboration across all levels of the healthcare system and community partners is essential. Further research is warranted on the effectives of this approach in pediatric obesity prevention and management.
The invention relates to modulating the SIRPa - CD47 interaction in order to increase hematopoietic stem cell engraftment and compounds therefor. In some embodiments, there is provided isolated SIRPa and CD47 polypeptides, fragments and fusion proteins for enhancing hematopoietic stem cell engraftment. Further there is provided methods for increasing hematopoietic stem cell engraftment through administration of the above polypeptides. According to a further aspect, there is provided an isolated polypeptide selected from the group consisting of a) a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS. 4-13; b) a polypeptide consisting of a fragment of an amino acid sequence selected from the group consisting of SEQ ID NOS. 4-13; and c) one of the polypeptide in a) and b) with up to 1 amino acid insertion, deletion or substitution for every 7 amino acids in length of the polypeptide, wherein the polypeptide binds human CD47.